{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:03:19Z","timestamp":1790071399489,"version":"4.0.1"},"publisher-location":"New York, NY","reference-count":136,"publisher":"Springer US","isbn-type":[{"value":"9781071655467","type":"print"},{"value":"9781071655474","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2027]]},"DOI":"10.1007\/978-1-0716-5547-4_6","type":"book-chapter","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:17:46Z","timestamp":1790068666000},"page":"93-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of Delivery Methods for Gene Editing"],"prefix":"10.1007","author":[{"given":"Bilge","family":"Debelec Butuner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"266","author":"C Liu","year":"2017","unstructured":"Liu C, Zhang L, Liu H, Cheng K (2017) Delivery Strategies of the CRISPR-Cas9 Gene-Editing System for Therapeutic Applications. J Control Release 266:17\u201326. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.012","journal-title":"J Control Release"},{"key":"6_CR2","doi-asserted-by":"crossref","unstructured":"Yip BH (2020) Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules 10:839","DOI":"10.3390\/biom10060839"},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"125470","DOI":"10.1016\/j.ijpharm.2025.125470","volume":"674","author":"S Honrath","year":"2025","unstructured":"Honrath S, Burger M, Leroux J-C (2025) Hurdles to healing: overcoming cellular barriers for viral and nonviral gene therapy. Int J Pharmaceut 674:125470","journal-title":"Int J Pharmaceut"},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.7150\/ijms.112724","volume":"22","author":"S Tang","year":"2025","unstructured":"Tang S, Chen X, Tong X, Zhu L (2025) Overcoming the delivery challenges in CRISPR\/Cas9 gene editing for effective cancer treatment: a review of delivery systems. Int J Med Sci 22:3625\u20133649","journal-title":"Int J Med Sci"},{"key":"6_CR5","doi-asserted-by":"crossref","unstructured":"Seijas A, Cora D, Novo M et al (2025) CRISPR\/Cas9 delivery systems to enhance gene editing efficiency. Int J Mol Sci 26:4420","DOI":"10.3390\/ijms26094420"},{"key":"6_CR6","doi-asserted-by":"crossref","unstructured":"Cavazza A, Molina-Est\u00e9vez FJ, Reyes \u00c1P et al (2025) Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST Action Working Group. Mol Ther Nucl Acids 36:102457","DOI":"10.1016\/j.omtn.2025.102457"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H et al. (2021) Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther 6:53","journal-title":"Sig Transduct Target Ther"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.3390\/ijms24097736","volume":"24","author":"X Li","year":"2023","unstructured":"Li X, Le Y, Zhang Z et al. (2023) Viral vector-based gene therapy. Int J Mol Sci 24:7736","journal-title":"Int J Mol Sci"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"e3107","DOI":"10.1002\/jgm.3107","volume":"21","author":"X Xu","year":"2019","unstructured":"Xu X, Wan T, Xin H et al. (2019) Delivery of CRISPR\/Cas9 for therapeutic genome editing. J Gene Med 21:e3107","journal-title":"J Gene Med"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2217\/fvl.13.112","volume":"8","author":"LM Drouin","year":"2013","unstructured":"Drouin LM, Agbandje-McKenna M (2013) Adeno-associated virus structural biology as a tool in vector development. Future Virol 8:1183\u20131199","journal-title":"Future Virol"},{"key":"6_CR11","unstructured":"Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: implications for neurodegenerative disease. Mol Ther Nucl Acids. https:\/\/www.cell.com\/molecular-therapy-family\/nucleic-acids\/fulltext\/S2162-2531(25)00189-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2162253125001891%3Fshowall%3Dtrue. Accessed 21 Mar 2026"},{"key":"6_CR12","unstructured":"In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness. Sci Transl Med. https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aay9101. Accessed 23 Mar 2026"},{"key":"6_CR13","unstructured":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/31937940\/. Accessed 23 Mar 2026"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","volume":"6","author":"JR Davis","year":"2022","unstructured":"Davis JR, Wang X, Witte IP et al. (2022) Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng 6:1272\u20131283. https:\/\/doi.org\/10.1038\/s41551-022-00911-4","journal-title":"Nat Biomed Eng"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1016\/j.ymthe.2022.07.001","volume":"30","author":"Z Gao","year":"2022","unstructured":"Gao Z, Ravendran S, Mikkelsen NS et al. (2022) A truncated reverse transcriptase enhances prime editing by split AAV vectors. Mol Ther 30:2942\u20132951. https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.001","journal-title":"Mol Ther"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2024","unstructured":"Davis JR, Banskota S, Levy JM et al. (2024) Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat Biotechnol 42:253\u2013264. https:\/\/doi.org\/10.1038\/s41587-023-01758-z","journal-title":"Nat Biotechnol"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.omtn.2023.08.018","volume":"33","author":"T Lan","year":"2023","unstructured":"Lan T, Chen H, Tang C et al. (2023) Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase. Mol Ther Nucleic Acids 33:890\u2013897. https:\/\/doi.org\/10.1016\/j.omtn.2023.08.018","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR18","unstructured":"Gene editing for CEP290-associated retinal degeneration. New Engl J Med. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2309915. Accessed 23 Mar 2026"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W et al. (2024) Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther 9:78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w","journal-title":"Sig Transduct Target Ther"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/crispr.2022.0051","volume":"5","author":"S Demirci","year":"2022","unstructured":"Demirci S, Essawi K, Germino-Watnick P et al. (2022) Advances in CRISPR delivery methods: perspectives and challenges. CRISPR J 5:660\u2013676. https:\/\/doi.org\/10.1089\/crispr.2022.0051","journal-title":"CRISPR J"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omtn.2018.08.007","volume":"13","author":"S S\u00e1nchez-Hern\u00e1ndez","year":"2018","unstructured":"S\u00e1nchez-Hern\u00e1ndez S, Gutierrez-Guerrero A, Mart\u00edn-Guerra R et al. (2018) The IS2 element improves transcription efficiency of integration-deficient lentiviral vector episomes. Mol Ther Nucleic Acids 13:16\u201328. https:\/\/doi.org\/10.1016\/j.omtn.2018.08.007","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR22","doi-asserted-by":"publisher","unstructured":"Jargalsaikhan B-E, Muto M, Ema M (2025) The era of gene therapy: the advancement of lentiviral vectors and their pseudotyping. Viruses 17. https:\/\/doi.org\/10.3390\/v17081036","DOI":"10.3390\/v17081036"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","volume":"21","author":"N Uchida","year":"2021","unstructured":"Uchida N, Drysdale CM, Nassehi T et al. (2021) Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol Ther Methods Clin Dev 21:121\u2013132. https:\/\/doi.org\/10.1016\/j.omtm.2021.02.022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.4110\/in.2026.26.e13","volume":"26","author":"Y Baek","year":"2026","unstructured":"Baek Y, Seo YR, Kim S et al. (2026) From ex vivo to in vivo: advances in lentiviral vector engineering for CAR-T therapy. Immune Netw 26:e13. https:\/\/doi.org\/10.4110\/in.2026.26.e13","journal-title":"Immune Netw"},{"issue":"Supplement 1","key":"6_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208461","volume":"144","author":"J Garcia","year":"2024","unstructured":"Garcia J (2024) A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies. Blood 144(Supplement 1), 1750.1-1750.1.","journal-title":"Blood"},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/ijms27041737","volume":"27","author":"S Pierini","year":"2026","unstructured":"Pierini S, Qureshi R, Pustylnikov S et al. (2026) In vivo CAR-T therapies-a new era of programmable immunity. Int J Mol Sci 27:1737. https:\/\/doi.org\/10.3390\/ijms27041737","journal-title":"Int J Mol Sci"},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/biomedicines14020369","volume":"14","author":"E Barbieri","year":"2026","unstructured":"Barbieri E, Heldt CL (2026) Challenges and opportunities in lentivirus viral vector manufacturing for in vivo applications. Biomedicines 14:369","journal-title":"Biomedicines"},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cells9040953","volume":"9","author":"F Tasca","year":"2020","unstructured":"Tasca F, Wang Q, Gon\u00e7alves MAFV (2020) Adenoviral vectors meet gene editing: a rising partnership for the genomic engineering of human stem cells and their progeny. Cells 9:953. https:\/\/doi.org\/10.3390\/cells9040953","journal-title":"Cells"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3390\/ijms21103643","volume":"21","author":"A Ricobaraza","year":"2020","unstructured":"Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L et al. (2020) High-capacity adenoviral vectors: expanding the scope of gene therapy. Int J Mol Sci 21:3643. https:\/\/doi.org\/10.3390\/ijms21103643","journal-title":"Int J Mol Sci"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","volume":"5","author":"C Li","year":"2021","unstructured":"Li C, Georgakopoulou A, Mishra A et al. (2021) In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal \u03b3-globin in \u03b2-YAC mice. Blood Adv 5:1122\u20131135. https:\/\/doi.org\/10.1182\/bloodadvances.2020003702","journal-title":"Blood Adv"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.1093\/nar\/gkab938","volume":"49","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liu J, Janssen JM et al. (2021) Broadening the reach and investigating the potential of prime editors through fully viral gene-deleted adenoviral vector delivery. Nucleic Acids Res 49:11986\u201312001. https:\/\/doi.org\/10.1093\/nar\/gkab938","journal-title":"Nucleic Acids Res"},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR (2023) Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet 24:161\u2013177. https:\/\/doi.org\/10.1038\/s41576-022-00541-1","journal-title":"Nat Rev Genet"},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/nar\/gkae057","volume":"52","author":"Q Wang","year":"2024","unstructured":"Wang Q, Capelletti S, Liu J et al. (2024) Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells. Nucleic Acids Res 52:2740\u20132757. https:\/\/doi.org\/10.1093\/nar\/gkae057","journal-title":"Nucleic Acids Res"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR (2023) Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet 24:161\u2013177. https:\/\/doi.org\/10.1038\/s41576-022-00541-1","journal-title":"Nat Rev Genet"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/pharmaceutics13101649","volume":"13","author":"H Cheng","year":"2021","unstructured":"Cheng H, Zhang F, Ding Y (2021) CRISPR\/Cas9 delivery system engineering for genome editing in therapeutic applications. Pharmaceutics 13:1649. https:\/\/doi.org\/10.3390\/pharmaceutics13101649","journal-title":"Pharmaceutics"},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","volume":"115","author":"Q Ding","year":"2014","unstructured":"Ding Q, Strong A, Patel KM et al. (2014) Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115:488\u2013492. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.304351","journal-title":"Circ Res"},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/vir.0.000139","volume":"96","author":"C Li","year":"2015","unstructured":"Li C, Guan X, Du T et al. (2015) Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9. J Gen Virol 96:2381\u20132393. https:\/\/doi.org\/10.1099\/vir.0.000139","journal-title":"J Gen Virol"},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","volume":"33","author":"NR Hackett","year":"2025","unstructured":"Hackett NR, Crystal RG (2025) Four decades of adenovirus gene transfer vectors: history and current use. Mol Ther 33:2192\u20132204. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.062","journal-title":"Mol Ther"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jconrel.2020.09.003","volume":"327","author":"P Boucher","year":"2020","unstructured":"Boucher P, Cui X, Curiel DT (2020) Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors. J Control Release 327:788\u2013800. https:\/\/doi.org\/10.1016\/j.jconrel.2020.09.003","journal-title":"J Control Release"},{"key":"6_CR40","doi-asserted-by":"publisher","unstructured":"Foley RA, Sims RA, Duggan EC et al (2022) Delivering the CRISPR\/Cas9 system for engineering gene therapies: recent cargo and delivery approaches for clinical translation. Front Bioeng Biotechnol 10. https:\/\/doi.org\/10.3389\/fbioe.2022.973326","DOI":"10.3389\/fbioe.2022.973326"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"e2307796121","DOI":"10.1073\/pnas.2307796121","volume":"121","author":"CA Tsuchida","year":"2024","unstructured":"Tsuchida CA, Wasko KM, Hamilton JR, Doudna JA (2024) Targeted nonviral delivery of genome editors in vivo. Proc Natl Acad Sci USA 121:e2307796121. https:\/\/doi.org\/10.1073\/pnas.2307796121","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1039\/D1BM01658J","volume":"10","author":"Y Lin","year":"2022","unstructured":"Lin Y, Wagner E, L\u00e4chelt U (2022) Non-viral delivery of the CRISPR\/Cas system: DNA versus RNA versus RNP. Biomater Sci 10:1166\u20131192. https:\/\/doi.org\/10.1039\/D1BM01658J","journal-title":"Biomater Sci"},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"2401632","DOI":"10.1002\/smtd.202401632","volume":"10","author":"F Wu","year":"2026","unstructured":"Wu F, Li N, Xiao Y et al. (2026) Lipid nanoparticles for delivery of CRISPR gene editing components. Small Methods 10:2401632. https:\/\/doi.org\/10.1002\/smtd.202401632","journal-title":"Small Methods"},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"121876","DOI":"10.1016\/j.biomaterials.2022.121876","volume":"291","author":"K Huang","year":"2022","unstructured":"Huang K, Zapata D, Tang Y et al. (2022) In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. Biomaterials 291:121876. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121876","journal-title":"Biomaterials"},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"e24606","DOI":"10.1016\/j.heliyon.2024.e24606","volume":"10","author":"A Mohammadian Farsani","year":"2024","unstructured":"Mohammadian Farsani A, Mokhtari N, Nooraei S et al. (2024) Lipid nanoparticles: the game-changer in CRISPR-Cas9 genome editing. Heliyon 10:e24606. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24606","journal-title":"Heliyon"},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"e2401632","DOI":"10.1002\/smtd.202401632","volume":"10","author":"F Wu","year":"2026","unstructured":"Wu F, Li N, Xiao Y et al. (2026) Lipid nanoparticles for delivery of CRISPR gene editing components. Small Methods 10:e2401632. https:\/\/doi.org\/10.1002\/smtd.202401632","journal-title":"Small Methods"},{"key":"6_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC et al. (2023) Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147:242\u2013253. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062132","journal-title":"Circulation"},{"key":"6_CR48","unstructured":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. New Engl J Med. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2511778. Accessed 27 Mar 2026"},{"key":"6_CR49","unstructured":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. https:\/\/www.nature.com\/articles\/s41565-020-0669-6. Accessed 27 Mar 2026"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y et al. (2023) Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 18:265\u2013291. https:\/\/doi.org\/10.1038\/s41596-022-00755-x","journal-title":"Nat Protoc"},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"13790","DOI":"10.1021\/acsnano.4c16617","volume":"19","author":"RM Haley","year":"2025","unstructured":"Haley RM, Padilla MS, El-Mayta RD et al. (2025) Lipid nanoparticles for in vivo lung delivery of CRISPR-Cas9 ribonucleoproteins allow gene editing of clinical targets. ACS Nano 19:13790\u201313804. https:\/\/doi.org\/10.1021\/acsnano.4c16617","journal-title":"ACS Nano"},{"key":"6_CR52","unstructured":"Transient macrophage depletion circumvents scavenging and redirects biodistribution of mRNA-lipid nanoparticles. ACS Nano. https:\/\/pubs.acs.org\/doi\/10.1021\/acsnano.5c02001. Accessed 27 Mar 2026"},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta A (2022) Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Control Release 342:345\u2013361. https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.013","journal-title":"J Control Release"},{"key":"6_CR54","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jconrel.2025.01.068","volume":"379","author":"A Vasudevan","year":"2025","unstructured":"Vasudevan A, Jozi\u0107 A, Curtis AG et al. (2025) Lipid nanoparticle-mediated intracameral mRNA delivery facilitates gene expression and editing in the anterior chamber of the eye. J Control Release 379:1022\u20131028. https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.068","journal-title":"J Control Release"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"115446","DOI":"10.1016\/j.addr.2024.115446","volume":"214","author":"K Mrksich","year":"2024","unstructured":"Mrksich K, Padilla MS, Mitchell MJ (2024) Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Adv Drug Deliv Rev 214:115446. https:\/\/doi.org\/10.1016\/j.addr.2024.115446","journal-title":"Adv Drug Deliv Rev"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymthe.2024.10.003","volume":"33","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Chen S, Hsiao S et al. (2025) Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption. Mol Ther 33:104\u2013118. https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.003","journal-title":"Mol Ther"},{"key":"6_CR57","unstructured":"A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell\u2013targeted delivery of gene-editing proteins. Sci Adv. https:\/\/www.science.org\/doi\/10.1126\/sciadv.ady5579. Accessed 27 Mar 2026"},{"key":"6_CR58","doi-asserted-by":"publisher","unstructured":"Lee H, Rho W-Y, Kim Y-H et al (2025) CRISPR-Cas9 gene therapy: non-viral delivery and stimuli-responsive nanoformulations. Molecules 30. https:\/\/doi.org\/10.3390\/molecules30030542","DOI":"10.3390\/molecules30030542"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","volume":"2","author":"BB Mendes","year":"2022","unstructured":"Mendes BB, Conniot J, Avital A et al. (2022) Nanodelivery of nucleic acids. Nat Rev Methods Primers 2:24. https:\/\/doi.org\/10.1038\/s43586-022-00104-y","journal-title":"Nat Rev Methods Primers"},{"key":"6_CR60","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ymthe.2018.07.019","volume":"26","author":"D Zhu","year":"2018","unstructured":"Zhu D, Shen H, Tan S et al. (2018) Nanoparticles based on poly (\u03b2-amino ester) and HPV16-targeting CRISPR\/shRNA as potential drugs for HPV16-related cervical malignancy. Mol Ther 26:2443\u20132455. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.019","journal-title":"Mol Ther"},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"1900386","DOI":"10.1002\/advs.201900386","volume":"6","author":"X Zhang","year":"2019","unstructured":"Zhang X, Xu C, Gao S et al. (2019) CRISPR\/Cas9 delivery mediated with hydroxyl-rich nanosystems for gene editing in aorta. Adv Sci 6:1900386. https:\/\/doi.org\/10.1002\/advs.201900386","journal-title":"Adv Sci"},{"key":"6_CR62","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12951-025-03448-1","volume":"23","author":"J Luo","year":"2025","unstructured":"Luo J, Cui Y, Xu L et al. (2025) Layered double hydroxides for regenerative nanomedicine and tissue engineering: recent advances and future perspectives. J Nanobiotechnol 23:370. https:\/\/doi.org\/10.1186\/s12951-025-03448-1","journal-title":"J Nanobiotechnol"},{"key":"6_CR63","doi-asserted-by":"publisher","unstructured":"Liu X, Gao M, Bao J (2025) Precisely targeted nanoparticles for CRISPR-Cas9 delivery in clinical applications. Nanomaterials 15. https:\/\/doi.org\/10.3390\/nano15070540","DOI":"10.3390\/nano15070540"},{"key":"6_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42456-8","volume":"9","author":"SG Patel","year":"2019","unstructured":"Patel SG, Sayers EJ, He L et al. (2019) Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep 9: 6298. https:\/\/doi.org\/10.1038\/s41598-019-42456-8","journal-title":"Sci Rep"},{"key":"6_CR65","doi-asserted-by":"publisher","unstructured":"de Morais CCP, de L, Correia EM, Bonamino MH, de Vasconcelos ZFM (2024) Cell-penetrating peptides and CRISPR-Cas9: a combined strategy for human genetic disease therapy. Hum Gene Ther 35:781\u2013797. https:\/\/doi.org\/10.1089\/hum.2024.020","DOI":"10.1089\/hum.2024.020"},{"key":"6_CR66","unstructured":"Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/37147433\/. Accessed 27 Mar 2026"},{"key":"6_CR67","unstructured":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/25357182\/. Accessed 27 Mar 2026"},{"key":"6_CR68","unstructured":"In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32485318\/. Accessed 27 Mar 2026"},{"key":"6_CR69","unstructured":"Revival of bioengineered proteins as carriers for nucleic acids\u2014 ScienceDirect. https:\/\/www.sciencedirect.com\/org\/science\/article\/pii\/S1043180224000594. Accessed 27 Mar 2026"},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ymthe.2023.02.013","volume":"31","author":"J R\u00e4dler","year":"2023","unstructured":"R\u00e4dler J, Gupta D, Zickler A, Andaloussi SE (2023) Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. Mol Ther 31:1231\u20131250. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.013","journal-title":"Mol Ther"},{"key":"6_CR71","doi-asserted-by":"publisher","first-page":"100032","DOI":"10.1016\/j.vesic.2023.100032","volume":"3","author":"V Sharma","year":"2024","unstructured":"Sharma V, Mukhopadhyay CD (2024) Exosome as drug delivery system: current advancements. Extracellular Vesicle 3:100032. https:\/\/doi.org\/10.1016\/j.vesic.2023.100032","journal-title":"Extracellular Vesicle"},{"key":"6_CR72","doi-asserted-by":"publisher","first-page":"101259","DOI":"10.1016\/j.omtm.2024.101259","volume":"32","author":"CA Ren\u00e9","year":"2024","unstructured":"Ren\u00e9 CA, Parks RJ (2024) Bioengineering extracellular vesicle cargo for optimal therapeutic efficiency. Mol Ther Method Clin Dev 32:101259. https:\/\/doi.org\/10.1016\/j.omtm.2024.101259","journal-title":"Mol Ther Method Clin Dev"},{"key":"6_CR73","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/pr9020356","volume":"9","author":"Y Han","year":"2021","unstructured":"Han Y, Jones TW, Dutta S et al. (2021) Overview and update on methods for cargo loading into extracellular vesicles. Processes 9:356. https:\/\/doi.org\/10.3390\/pr9020356","journal-title":"Processes"},{"key":"6_CR74","doi-asserted-by":"publisher","first-page":"102040","DOI":"10.1016\/j.omtn.2023.102040","volume":"34","author":"Y Lu","year":"2023","unstructured":"Lu Y, Godbout K, Lamothe G, Tremblay JP (2023) CRISPR-Cas9 delivery strategies with engineered extracellular vesicles. Mol Ther Nucleic Acids 34:102040. https:\/\/doi.org\/10.1016\/j.omtn.2023.102040","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR75","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1021\/acssynbio.8b00192","volume":"7","author":"D Lain\u0161\u010dek","year":"2018","unstructured":"Lain\u0161\u010dek D, Kadunc L, Keber MM et al. (2018) Delivery of an artificial transcription regulator dCas9-VPR by extracellular vesicles for therapeutic gene activation. ACS Synth Biol 7:2715\u20132725. https:\/\/doi.org\/10.1021\/acssynbio.8b00192","journal-title":"ACS Synth Biol"},{"key":"6_CR76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jconrel.2023.12.050","volume":"366","author":"X Pan","year":"2024","unstructured":"Pan X, Li Y, Huang P et al. (2024) Extracellular vesicles for developing targeted hearing loss therapy. J Control Release 366:460\u2013478. https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.050","journal-title":"J Control Release"},{"key":"6_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim SM, Yang Y, Oh SJ et al. (2017) Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J Control Release 266:8\u201316. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.013","journal-title":"J Control Release"},{"key":"6_CR78","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.ymthe.2022.05.023","volume":"30","author":"N Majeau","year":"2022","unstructured":"Majeau N, Fortin-Archambault A, G\u00e9rard C et al. (2022) Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene. Mol Ther 30:2429\u20132442. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.023","journal-title":"Mol Ther"},{"key":"6_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14957-y","volume":"11","author":"P Gee","year":"2020","unstructured":"Gee P, Lung MSY, Okuzaki Y et al. (2020) Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun 11: 1334. https:\/\/doi.org\/10.1038\/s41467-020-14957-y","journal-title":"Nat Commun"},{"key":"6_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59377-y","volume":"16","author":"X Liang","year":"2025","unstructured":"Liang X, Gupta D, Xie J et al. (2025) Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat Commun 16: 4028. https:\/\/doi.org\/10.1038\/s41467-025-59377-y","journal-title":"Nat Commun"},{"key":"6_CR81","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.7150\/thno.92133","volume":"14","author":"S Dubey","year":"2024","unstructured":"Dubey S, Chen Z, Jiang YJ et al. (2024) Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR\/Cas9 genome editing. Theranostics 14:2777\u20132793. https:\/\/doi.org\/10.7150\/thno.92133","journal-title":"Theranostics"},{"key":"6_CR82","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.1002\/jev2.12389","volume":"13","author":"NF Ilahibaks","year":"2024","unstructured":"Ilahibaks NF, Kluiver TA, de Jong OG et al. (2024) Extracellular vesicle-mediated delivery of CRISPR\/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes. J Extracell Vesicles 13:12389. https:\/\/doi.org\/10.1002\/jev2.12389","journal-title":"J Extracell Vesicles"},{"key":"6_CR83","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41551-023-01142-x","volume":"8","author":"DM Stranford","year":"2024","unstructured":"Stranford DM, Simons LM, Berman KE et al. (2024) Bioengineering multifunctional extracellular vesicles for targeted delivery of biologics to T cells. Nat Biomed Eng 8:397\u2013414. https:\/\/doi.org\/10.1038\/s41551-023-01142-x","journal-title":"Nat Biomed Eng"},{"key":"6_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03352-8","volume":"23","author":"S Mehdizadeh","year":"2025","unstructured":"Mehdizadeh S, Mamaghani M, Hassanikia S et al. (2025) Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies. J Nanobiotechnology 23: 329. https:\/\/doi.org\/10.1186\/s12951-025-03352-8","journal-title":"J Nanobiotechnology"},{"key":"6_CR85","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","volume":"38","author":"J van Haasteren","year":"2020","unstructured":"van Haasteren J, Li J, Scheideler OJ et al. (2020) The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat Biotechnol 38:845\u2013855. https:\/\/doi.org\/10.1038\/s41587-020-0565-5","journal-title":"Nat Biotechnol"},{"key":"6_CR86","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.7150\/thno.43465","volume":"10","author":"AK Fajrial","year":"2020","unstructured":"Fajrial AK, He QQ, Wirusanti NI et al. (2020) A review of emerging physical transfection methods for CRISPR\/Cas9-mediated gene editing. Theranostics 10:5532\u20135549. https:\/\/doi.org\/10.7150\/thno.43465","journal-title":"Theranostics"},{"key":"6_CR87","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.1614775114","volume":"114","author":"W Wu","year":"2017","unstructured":"Wu W, Lu Z, Li F et al. (2017) Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci USA 114:1660\u20131665. https:\/\/doi.org\/10.1073\/pnas.1614775114","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR88","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1038\/mtna.2016.92","volume":"5","author":"MC Latella","year":"2016","unstructured":"Latella MC, Di Salvo MT, Cocchiarella F et al. (2016) In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR\/Cas9 in the mouse retina. Mol Ther Nucleic Acids 5:e389. https:\/\/doi.org\/10.1038\/mtna.2016.92","journal-title":"Mol Ther Nucleic Acids"},{"key":"6_CR89","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nmat4249","volume":"14","author":"C Chiappini","year":"2015","unstructured":"Chiappini C, De Rosa E, Martinez JO et al. (2015) Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nat Mater 14:532\u2013539. https:\/\/doi.org\/10.1038\/nmat4249","journal-title":"Nat Mater"},{"key":"6_CR90","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu L, Wang J, Liu Y et al. (2019) CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med 381:1240\u20131247. https:\/\/doi.org\/10.1056\/NEJMoa1817426","journal-title":"N Engl J Med"},{"key":"6_CR91","doi-asserted-by":"publisher","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science 367:eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365","DOI":"10.1126\/science.aba7365"},{"key":"6_CR92","doi-asserted-by":"publisher","unstructured":"Taghdiri M, Mussolino C (2024) Viral and non-viral systems to deliver gene therapeutics to clinical targets. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25137333","DOI":"10.3390\/ijms25137333"},{"key":"6_CR93","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C et al. (2017) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23:2255\u20132266. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1300","journal-title":"Clin Cancer Res"},{"key":"6_CR94","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","volume":"19","author":"M Lotfi","year":"2023","unstructured":"Lotfi M, Morshedi Rad D, Mashhadi SS et al. (2023) Recent advances in CRISPR\/Cas9 delivery approaches for therapeutic gene editing of stem cells. Stem Cell Rev Rep 19:2576\u20132596. https:\/\/doi.org\/10.1007\/s12015-023-10585-3","journal-title":"Stem Cell Rev Rep"},{"key":"6_CR95","doi-asserted-by":"publisher","first-page":"828489","DOI":"10.3389\/fgeed.2022.828489","volume":"4","author":"BC Houghton","year":"2022","unstructured":"Houghton BC, Panchal N, Haas SA et al. (2022) Genome editing with TALEN, CRISPR-Cas9 and CRISPR-Cas12a in combination with AAV6 homology donor restores T cell function for XLP. Front Genome Ed 4:828489. https:\/\/doi.org\/10.3389\/fgeed.2022.828489","journal-title":"Front Genome Ed"},{"key":"6_CR96","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD et al. (2021) CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia. N Engl J Med 384:252\u2013260. https:\/\/doi.org\/10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"6_CR97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1167\/iovs.67.2.60","volume":"67","author":"J Chen","year":"2026","unstructured":"Chen J, Davison CW, Ellis J et al. (2026) CRISPR base editing correction of TGFBI mutations in autosomal dominant corneal dystrophies. Invest Ophthalmol Vis Sci 67:60. https:\/\/doi.org\/10.1167\/iovs.67.2.60","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6_CR98","doi-asserted-by":"publisher","first-page":"107822","DOI":"10.1016\/j.bioelechem.2021.107822","volume":"140","author":"Y Mi","year":"2021","unstructured":"Mi Y, Xu J, Liu Q et al. (2021) Single-cell electroporation with high-frequency nanosecond pulse bursts: simulation considering the irreversible electroporation effect and experimental validation. Bioelectrochemistry 140:107822. https:\/\/doi.org\/10.1016\/j.bioelechem.2021.107822","journal-title":"Bioelectrochemistry"},{"key":"6_CR99","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00232-023-00283-z","volume":"256","author":"N Mondal","year":"2023","unstructured":"Mondal N, Yadav KS, Dalal DC (2023) Enhanced drug uptake on application of electroporation in a single-cell model. J Membr Biol 256:243\u2013255. https:\/\/doi.org\/10.1007\/s00232-023-00283-z","journal-title":"J Membr Biol"},{"key":"6_CR100","doi-asserted-by":"publisher","first-page":"2000061","DOI":"10.1002\/anbr.202000061","volume":"1","author":"MA Pop","year":"2021","unstructured":"Pop MA, Almquist BD (2021) Controlled delivery of microRNAs into primary cells using nanostraw technology. Adv Nanobiomed Res 1:2000061. https:\/\/doi.org\/10.1002\/anbr.202000061","journal-title":"Adv Nanobiomed Res"},{"key":"6_CR101","doi-asserted-by":"publisher","first-page":"30295","DOI":"10.1039\/d2ra05119b","volume":"12","author":"M Lard","year":"2022","unstructured":"Lard M, Ho BD, Beech JP et al. (2022) Use of dielectrophoresis for directing T cells to microwells before nanostraw transfection: modelling and experiments. RSC Adv 12:30295\u201330303. https:\/\/doi.org\/10.1039\/d2ra05119b","journal-title":"RSC Adv"},{"key":"6_CR102","doi-asserted-by":"publisher","first-page":"101327","DOI":"10.1016\/j.jhepr.2025.101327","volume":"7","author":"T Chen","year":"2025","unstructured":"Chen T, Barzi M, Furey N et al. (2025) CRISPR\/Cas9 gene therapy increases the risk of tumorigenesis in the mouse model of hereditary tyrosinemia type I. JHEP Rep 7:101327. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101327","journal-title":"JHEP Rep"},{"key":"6_CR103","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/pharmaceutics17050656","volume":"17","author":"V Monteagudo","year":"2025","unstructured":"Monteagudo V, Flores LCB, Lopes M et al. (2025) Newborn intravenous injection of liposomal CRISPR\/Cas9 complex has no incidence of off-targets or tumors in mice. Pharmaceutics 17:656. https:\/\/doi.org\/10.3390\/pharmaceutics17050656","journal-title":"Pharmaceutics"},{"key":"6_CR104","doi-asserted-by":"publisher","first-page":"110697","DOI":"10.1016\/j.exer.2025.110697","volume":"261","author":"D Xie","year":"2025","unstructured":"Xie D, Wang J, Huang L et al. (2025) A novel X-linked retinitis pigmentosa beagle dog model for ophthalmic research established rapidly by editing the RPGR gene in zygotes. Exp Eye Res 261:110697. https:\/\/doi.org\/10.1016\/j.exer.2025.110697","journal-title":"Exp Eye Res"},{"key":"6_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65724-w","volume":"16","author":"F Zhang","year":"2025","unstructured":"Zhang F, Peng Y, Fan D et al. (2025) Engineering a CRISPR-associated IscB system for developing miniature genome-editing tools in human cells and mouse embryos. Nat Commun 16: 10693. https:\/\/doi.org\/10.1038\/s41467-025-65724-w","journal-title":"Nat Commun"},{"key":"6_CR106","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ame2.70107","volume":"9","author":"W Chen","year":"2026","unstructured":"Chen W, Zhang X, Fan R et al. (2026) Generating golden Syrian hamsters with conditional alleles via zygote microinjection of CRISPR\/Cas9. Animal Model Exp Med 9:308\u2013318. https:\/\/doi.org\/10.1002\/ame2.70107","journal-title":"Animal Model Exp Med"},{"key":"6_CR107","doi-asserted-by":"publisher","first-page":"100193","DOI":"10.1016\/j.mtbio.2021.100193","volume":"13","author":"P Chakrabarty","year":"2022","unstructured":"Chakrabarty P, Gupta P, Illath K et al. (2022) Microfluidic mechanoporation for cellular delivery and analysis. Mater Today Bio 13:100193. https:\/\/doi.org\/10.1016\/j.mtbio.2021.100193","journal-title":"Mater Today Bio"},{"key":"6_CR108","doi-asserted-by":"publisher","unstructured":"Zhang G, Mu R, Ma Y, Li B (2025) Intracellular delivery enabled by squeezing mechanoporation. Small Methods e2500338. https:\/\/doi.org\/10.1002\/smtd.202500338","DOI":"10.1002\/smtd.202500338"},{"key":"6_CR109","doi-asserted-by":"publisher","first-page":"e1500454","DOI":"10.1126\/sciadv.1500454","volume":"1","author":"X Han","year":"2015","unstructured":"Han X, Liu Z, Jo MC et al. (2015) CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation. Sci Adv 1:e1500454. https:\/\/doi.org\/10.1126\/sciadv.1500454","journal-title":"Sci Adv"},{"key":"6_CR110","doi-asserted-by":"publisher","first-page":"e1600007","DOI":"10.1002\/adbi.201600007","volume":"1","author":"X Han","year":"2017","unstructured":"Han X, Liu Z, Ma Y et al. (2017) Cas9 ribonucleoprotein delivery via microfluidic cell-deformation chip for human T-cell genome editing and immunotherapy. Adv Biosyst 1:e1600007. https:\/\/doi.org\/10.1002\/adbi.201600007","journal-title":"Adv Biosyst"},{"key":"6_CR111","doi-asserted-by":"publisher","unstructured":"Kim Y-J, Bang S, Chung AJ (2026) Safe and efficient CRISPR genome editing of primary human T cells using a droplet-based cell mechanoporation platform. Small n\/a:e12553. https:\/\/doi.org\/10.1002\/smll.202512553","DOI":"10.1002\/smll.202512553"},{"key":"6_CR112","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.cell.2015.03.028","volume":"161","author":"DS D\u2019Astolfo","year":"2015","unstructured":"D\u2019Astolfo DS, Pagliero RJ, Pras A et al. (2015) Efficient intracellular delivery of native proteins. Cell 161:674\u2013690. https:\/\/doi.org\/10.1016\/j.cell.2015.03.028","journal-title":"Cell"},{"key":"6_CR113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jbiotec.2021.07.006","volume":"338","author":"WM Kholosy","year":"2021","unstructured":"Kholosy WM, Visscher M, Ogink K et al. (2021) Simple, fast and efficient iTOP-mediated delivery of CRISPR\/Cas9 RNP in difficult-to-transduce human cells including primary T cells. J Biotechnol 338:71\u201380. https:\/\/doi.org\/10.1016\/j.jbiotec.2021.07.006","journal-title":"J Biotechnol"},{"key":"6_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/srep11406","volume":"5","author":"G Takahashi","year":"2015","unstructured":"Takahashi G, Gurumurthy CB, Wada K et al. (2015) GONAD: genome-editing via oviductal nucleic acids delivery system: a novel microinjection independent genome engineering method in mice. Sci Rep 5: 11406. https:\/\/doi.org\/10.1038\/srep11406","journal-title":"Sci Rep"},{"key":"6_CR115","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1538\/expanim.25-0036","volume":"74","author":"A Bold-Erdene","year":"2025","unstructured":"Bold-Erdene A, Miura K, Yamasaki N et al. (2025) Effect of gamma-ray exposure on the genome-editing efficiency of improved genome-editing via oviductal nucleic acids delivery (i-GONAD). Exp Anim 74:457\u2013462. https:\/\/doi.org\/10.1538\/expanim.25-0036","journal-title":"Exp Anim"},{"key":"6_CR116","doi-asserted-by":"publisher","unstructured":"Leonova EI, Chirinskaite AV, Akhmarov II et al (2025) Improved genome editing via oviductal nucleic acids delivery-based in vivo electroporation technique for knockout mice generation. J Vis Exp. https:\/\/doi.org\/10.3791\/68704","DOI":"10.3791\/68704"},{"key":"6_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34601-6","volume":"8","author":"J Yen","year":"2018","unstructured":"Yen J, Fiorino M, Liu Y et al. (2018) TRIAMF: a new method for delivery of Cas9 ribonucleoprotein complex to human hematopoietic stem cells. Sci Rep 8: 16304. https:\/\/doi.org\/10.1038\/s41598-018-34601-6","journal-title":"Sci Rep"},{"key":"6_CR118","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","volume":"52","author":"D Wilbie","year":"2019","unstructured":"Wilbie D, Walther J, Mastrobattista E (2019) Delivery aspects of CRISPR\/Cas for in vivo genome editing. Acc Chem Res 52:1555\u20131564. https:\/\/doi.org\/10.1021\/acs.accounts.9b00106","journal-title":"Acc Chem Res"},{"key":"6_CR119","doi-asserted-by":"publisher","unstructured":"Lyu P, Lu B (2022) New advances in using virus-like particles and related technologies for eukaryotic genome editing delivery. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23158750","DOI":"10.3390\/ijms23158750"},{"key":"6_CR120","doi-asserted-by":"publisher","first-page":"102785","DOI":"10.1016\/j.copbio.2022.102785","volume":"78","author":"B Ikwuagwu","year":"2022","unstructured":"Ikwuagwu B, Tullman-Ercek D (2022) Virus-like particles for drug delivery: a review of methods and applications. Curr Opin Biotechnol 78:102785. https:\/\/doi.org\/10.1016\/j.copbio.2022.102785","journal-title":"Curr Opin Biotechnol"},{"key":"6_CR121","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life10120366","volume":"10","author":"P Lyu","year":"2020","unstructured":"Lyu P, Wang L, Lu B (2020) Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome Editing. Life 10:366. https:\/\/doi.org\/10.3390\/life10120366","journal-title":"Life"},{"key":"6_CR122","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel M, Lash B, Song J et al. (2021) Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373:882\u2013889. https:\/\/doi.org\/10.1126\/science.abg6155","journal-title":"Science"},{"key":"6_CR123","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","volume":"42","author":"M An","year":"2024","unstructured":"An M, Raguram A, Du SW et al. (2024) Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol 42:1526\u20131537. https:\/\/doi.org\/10.1038\/s41587-023-02078-y","journal-title":"Nat Biotechnol"},{"key":"6_CR124","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota S, Raguram A, Suh S et al. (2022) Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185:250\u2013265. https:\/\/doi.org\/10.1016\/j.cell.2021.12.021 e16","journal-title":"Cell"},{"key":"6_CR125","doi-asserted-by":"publisher","first-page":"109207","DOI":"10.1016\/j.celrep.2021.109207","volume":"35","author":"JR Hamilton","year":"2021","unstructured":"Hamilton JR, Tsuchida CA, Nguyen DN et al. (2021) Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Reports 35:109207. https:\/\/doi.org\/10.1016\/j.celrep.2021.109207","journal-title":"Cell Reports"},{"key":"6_CR126","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/gt.2016.27","volume":"23","author":"JG Choi","year":"2016","unstructured":"Choi JG, Dang Y, Abraham S et al. (2016) Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther 23:627\u2013633. https:\/\/doi.org\/10.1038\/gt.2016.27","journal-title":"Gene Ther"},{"key":"6_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s43246-022-00229-3","volume":"3","author":"AP Biela","year":"2022","unstructured":"Biela AP, Naskalska A, Fatehi F et al. (2022) Programmable polymorphism of a virus-like particle. Commun Mater 3:7. https:\/\/doi.org\/10.1038\/s43246-022-00229-3","journal-title":"Commun Mater"},{"key":"6_CR128","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/hum.2024.105","volume":"35","author":"JH Janns","year":"2024","unstructured":"Janns JH, Mikkelsen JG (2024) Gene editing by ferrying of CRISPR\/Cas ribonucleoprotein complexes in enveloped virus-derived particles. Hum Gene Ther 35:604\u2013616. https:\/\/doi.org\/10.1089\/hum.2024.105","journal-title":"Hum Gene Ther"},{"key":"6_CR129","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1089\/hum.2024.258","volume":"36","author":"LL Dipalo","year":"2025","unstructured":"Dipalo LL, Mikkelsen JG, Gijsbers R, Carlon MS (2025) Trojan Horse-like vehicles for CRISPR-Cas delivery: engineering extracellular vesicles and virus-like particles for precision gene editing in cystic fibrosis. Hum Gene Ther 36:1021\u20131052. https:\/\/doi.org\/10.1089\/hum.2024.258","journal-title":"Hum Gene Ther"},{"key":"6_CR130","doi-asserted-by":"publisher","first-page":"115555","DOI":"10.1016\/j.bcp.2023.115555","volume":"212","author":"M Farzanehpour","year":"2023","unstructured":"Farzanehpour M, Miri A, Alvanegh AG, Gouvarchinghaleh HE (2023) Viral vectors, exosomes, and vexosomes: potential armamentarium for delivering CRISPR\/Cas to cancer cells. Biochem Pharmacol 212:115555. https:\/\/doi.org\/10.1016\/j.bcp.2023.115555","journal-title":"Biochem Pharmacol"},{"key":"6_CR131","doi-asserted-by":"publisher","first-page":"1747206","DOI":"10.1080\/20013078.2020.1747206","volume":"9","author":"H Saari","year":"2020","unstructured":"Saari H, Turunen T, L\u00f5hmus A et al. (2020) Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery. J Extracell Vesicles 9:1747206. https:\/\/doi.org\/10.1080\/20013078.2020.1747206","journal-title":"J Extracell Vesicles"},{"key":"6_CR132","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.4155\/tde.11.83","volume":"2","author":"MJA Wood","year":"2011","unstructured":"Wood MJA, O\u2019Loughlin AJ, Samira L (2011) Exosomes and the blood-brain barrier: implications for neurological diseases. Ther Deliv 2:1095\u20131099. https:\/\/doi.org\/10.4155\/tde.11.83","journal-title":"Ther Deliv"},{"key":"6_CR133","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.omtm.2019.06.005","volume":"14","author":"NS Orefice","year":"2019","unstructured":"Orefice NS, Souchet B, Braudeau J et al. (2019) Real-time monitoring of exosome enveloped-AAV spreading by endomicroscopy approach: a new tool for gene delivery in the brain. Mol Ther Methods Clin Dev 14:237\u2013251. https:\/\/doi.org\/10.1016\/j.omtm.2019.06.005","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6_CR134","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omtm.2018.07.006","volume":"10","author":"E Hudry","year":"2018","unstructured":"Hudry E, Andres-Mateos E, Lerner EP et al. (2018) Efficient gene transfer to the central nervous system by single-stranded Anc80L65. Mol Ther Methods Clin Dev 10:197\u2013209. https:\/\/doi.org\/10.1016\/j.omtm.2018.07.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6_CR135","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","volume":"1","author":"A Meliani","year":"2017","unstructured":"Meliani A, Boisgerault F, Fitzpatrick Z et al. (2017) Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv 1:2019\u20132031. https:\/\/doi.org\/10.1182\/bloodadvances.2017010181","journal-title":"Blood Adv"},{"key":"6_CR136","doi-asserted-by":"publisher","first-page":"56","DOI":"10.17691\/stm2025.17.6.06","volume":"17","author":"EI Shchukina","year":"2025","unstructured":"Shchukina EI, Mazunin IO, Eremin II, Moskalev AA (2025) Gene therapy techniques and delivery methods. Sovrem Tekhnologii Med 17:56\u201367. https:\/\/doi.org\/10.17691\/stm2025.17.6.06","journal-title":"Sovrem Tekhnologii Med"}],"container-title":["Methods in Molecular Biology","CRISPR Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5547-4_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:17:59Z","timestamp":1790068679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5547-4_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"ISBN":["9781071655467","9781071655474"],"references-count":136,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5547-4_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"23 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author declares no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}